The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Exscientia & University of Oxford Launch “Xcellomics” Program

10 Mar 2022

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery Program open at no-cost to any academic researcher interested in submitting a proposal OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a... Read more

Mirobio Continues Expansion of Team With Key Appointments

08 Mar 2022

MIROBIO CONTINUES EXPANSION OF EXECUTIVE LEADERSHIP TEAM WITH KEY APPOINTMENTS TO ADVANCE DEVELOPMENT OF CHECKPOINT AGONIST ANTIBODIES FOR AUTOIMMUNE DISEASE Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as Chief Scientific Officer after leading MiroBio’s R&D efforts since October 2020 Enhanced leadership... Read more

OMass Establishes Scientific Advisory Board – Experts in Biophysical Approaches to Drug Discovery

08 Mar 2022

Oxford, United Kingdom – 7 March 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the establishment of its scientific advisory board (SAB), comprising of world-renowned experts across biophysical technologies. The Company’s newly formed SAB will guide OMass’ mission of improving... Read more

Renowned biotechnology exec & former Alnylam CEO John Maraganore has joined Evox Therapeutics

28 Feb 2022

Renowned biotechnology executive and former Alnylam CEO John Maraganore has joined Evox Therapeutics Ltd as an advisor. The company said – ‘We look forward to his counsel as we advance our exosome therapeutics programs in rare diseases.’ Read more

Enara Bio announces the appointment of T-cell therapy leader  Dr. Sophie Papa as Chief Medical Officer

01 Feb 2022

Enara Bio announces the appointment of T-cell therapy leader Dr. Sophie Papa as Chief Medical Officer Oxford, UK – 1st February 2022. Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens, announces the appointment of Dr. Sophie Papa, FRCP, PhD as Chief Medical Officer. Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and... Read more

News